Loading...
XMAD
FAE
Market cap1.65bUSD
Sep 17, Last price  
4.62EUR
1D
0.87%
1Q
1.32%
Jan 2017
37.50%
Name

Faes Farma SA

Chart & performance

D1W1MN
XMAD:FAE chart
P/E
18.07
P/S
2.36
EPS
0.26
Div yield, %
3.87%
Shrs. gr., 5y
1.40%
Rev. gr., 5y
9.93%
Revenues
610m
+23.66%
185,187,000185,940,000194,180,000131,406,000202,507,000190,224,000176,109,000180,394,000191,742,000204,724,000228,635,000274,576,000324,312,000357,398,000380,240,000398,557,000438,754,000451,168,000493,647,000610,464,000
Net income
80m
-28.49%
22,772,00022,149,00019,615,00018,161,00020,002,00014,181,00019,518,00022,605,00025,334,00030,361,00036,591,00042,221,00051,592,00063,962,00072,549,00082,390,00089,496,00091,902,000111,360,00079,630,000
CFO
78m
-32.02%
19,930,00013,044,00034,308,00016,946,00015,238,00019,975,00023,872,00031,647,00032,259,00040,912,00049,625,00041,727,00059,336,00067,585,00078,489,00079,645,000106,788,000100,969,000115,468,00078,490,000
Dividend
Jul 02, 20260.087 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research, development, manufacture, and distribution of both finished medicinal products and crucial raw materials. Its extensive operations span Spain and a multitude of international markets. The company's comprehensive product line encompasses prescription drugs, generic alternatives, over-the-counter (OTC) remedies, nutritional supplements, infant formula, and various other health-related items. Among its diverse offerings are Actimag (a magnesium pidolate), the anti-allergic Bilaxten, the anti-infective Bronquidiazina CR, Claversal for ulcerative colitis and Crohn's disease, the corticoid Dezacor, the anti-inflammatory Dolotren (also available as Dolotren Gel), Dynamogen (an anti-anorexic), Ferroprotina (an anti-anaemic), Hidroferol, Lipofen, Positon for dermatological conditions, strength-enhancing products such as Potenciator and Surmenalit, the laxative Pruina, the muscle relaxant and analgesic Robaxisal Compuesto, Trausan (a citicoline-based product), the venous vasoprotector Venosmil (and Venosmil Gel), and the anti-influenza medication Yendol. Furthermore, Faes Farma provides key active pharmaceutical ingredients, including Bilastine (an antihistamine molecule for allergic rhinitis, conjunctivitis, and urticaria), Calcifediol for bone metabolism, Deflazacort for treating osteoarticular diseases, Hidrosmin for venous insufficiency, and Mesalazine for digestive problems. The firm also engages in significant export activities. Founded in 1933, Faes Farma, S.A. is headquartered in Leioa, Spain.

Related entities

Subsidiaries (3)
COLPHARMA S.R.L.
FAES FARMA MEXICO SA DE CV
LAZLO INTERNATIONAL SA

Key people

Mariano Ucar Angulo
Chairman of the Board, Other External Director · since 2024
Valentin Ruiz Unamunzaga
Chief Financial Officer · since 2024
Carlos Gutierrez Aguero
Chief People Officer · since 2024
Jaime Lopez
Global Head - IT
Alberto Fernandez Fernandez
Chief Marketing and Portfolio Strategy Officer · since 2024
Isabel Najera
Chief Scientific and Medical Officer
Mariana Soroa Zubiria
Chief GRC & Internal Audit Officer · since 2024
Eduardo Recoder De La Cuadra
Chief Executive Officer, Executive Director · since 2024
Maria Marin
Head - Investor Relations & External Comms
Xavier Arnaud
Chief Business Development Officer · since 2024
Helder Cassis
Country Manager, Portugal · since 2024
Jose Luis Diaz Capote
Chief International Business Officer · since 2024
German Fernandez-Cano Diaz
Chief Farm Faes Business Officer · since 2024
Esther Mosquera
Country Manager, Spain
Tom Van Ommen
Head - Corporate Controlling
Juan Veiga
Head - Transformation Office
Non-Member Secretary of the Board · since 2022
Carmen Basagoiti Pastor
Proprietary Director · since 2011
Gonzalo Fernandez de Valderrama Iribarnegaray
Proprietary Director · since 2022
Inigo Zavala Ortiz de la Torre
Proprietary Director · since 1994
IPO date
Mar 25, 1994
Employees
1,764
Domiciled in
ES
Incorporated in
ES
Headquarters & legal address
AVENIDA AUTONOMIA, 10-
Leioa 48940
ES

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT